Notable
Lutetium Lu 177 JH020002 Injection · Advanced Prostate Cancer
Primary completion pushed from May 2026 to Dec 2026
Bivision Pharmaceuticals, Inc.Phase 1/2 NCT06139575 Registry history of NCT06139575 on ClinicalTrials.gov (opens the registry)
Updated